Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
62
LABS.TO Quote, Financials, Valuation and Earnings
Last price:
$0.08
Seasonality move
:
-4.2%
Day range:
$0.07 - $0.08
52-week range:
$0.06 - $0.12
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.68x
P/B ratio:
0.83x
Volume:
37.9K
Avg. volume:
382.6K
1-year change:
15.38%
Market cap:
$31.6M
Revenue:
$42M
EPS (TTM):
-$0.02
Analysts' Opinion
-
Consensus RatingMediPharm Labs Corp. has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, MediPharm Labs Corp. has an estimated upside of 33.33% from its current price of $0.08.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing -- downside risk from its current price of $0.08.
Fair Value
-
According to the consensus of 1 analyst, MediPharm Labs Corp. has 33.33% upside to fair value with a price target of -- per share.
LABS.TO vs. S&P 500
-
Over the past 5 trading days, MediPharm Labs Corp. has underperformed the S&P 500 by -1.38% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
MediPharm Labs Corp. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
MediPharm Labs Corp. has grown year-over-year revenues for 11 quarters straight. In the most recent quarter MediPharm Labs Corp. reported revenues of $11.4M.
Earnings Growth
-
MediPharm Labs Corp. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter MediPharm Labs Corp. reported earnings per share of -$0.01.
Enterprise value:
21.4M
EV / Invested capital:
--
Price / LTM sales:
0.68x
EV / EBIT:
--
EV / Revenue:
0.46x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-3.08x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$13M
Return On Assets:
-15.58%
Net Income Margin (TTM):
-17.41%
Return On Equity:
-19.19%
Return On Invested Capital:
-18.99%
Operating Margin:
-18.68%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $29.5M | $39.1M | $46.1M | $9.8M | $11.4M | |
| Gross Profit | $2.9M | $11.9M | $13M | $3.6M | $2.4M | |
| Operating Income | -$21.8M | -$11.5M | -$8.9M | -$2M | -$2.1M | |
| EBITDA | -$19.5M | -$8.8M | -$7.1M | -$1.4M | -$1.7M | |
| Diluted EPS | -$0.05 | -$0.03 | -$0.02 | -$0.01 | -$0.01 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $84.9M | $52.2M | $41.7M | $34.6M | $27.9M | |
| Total Assets | $118.2M | $71.2M | $68M | $55.8M | $46.6M | |
| Current Liabilities | $15.5M | $10.7M | $12.7M | $10.8M | $8.7M | |
| Total Liabilities | $15.6M | $10.8M | $12.8M | $10.8M | $8.7M | |
| Total Equity | $102.6M | $60.5M | $55.2M | $45M | $37.9M | |
| Total Debt | $2.3M | $131K | $905K | $654K | $423K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$13.4M | -$1.9M | -$6.8M | -$642K | -$111K | |
| Cash From Investing | $8.3M | $4.8M | $4.6M | -$33K | $459K | |
| Cash From Financing | -$1.1M | -$2.3M | -$292K | -$2.2M | -$120K | |
| Free Cash Flow | -$14.1M | -$2.1M | -$6.9M | -$675K | -$127K | |
LABS.TO
Sector
Market Cap
$31.6M
$28.2M
Price % of 52-Week High
--
51.2%
Dividend Yield
0%
0%
Shareholder Yield
1.47%
-1.54%
1-Year Price Total Return
15.39%
-18.1%
Beta (5-Year)
0.637
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$0.07
200-day SMA
Sell
Level
$0.08
Bollinger Bands (100)
Buy
Level
0.06 - 0.08
Chaikin Money Flow
Sell
Level
-2.3M
20-day SMA
Buy
Level
$0.07
Relative Strength Index (RSI14)
Buy
Level
61.98
ADX Line
Buy
Level
33.74
Williams %R
Sell
Level
0
50-day SMA
Buy
Level
$0.07
MACD (12, 26)
Sell
Level
0.00
25-day Aroon Oscillator
Buy
Level
72
On Balance Volume
Sell
Level
-736.5K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-2.9003)
Buy
CA Score
(Annual)
Level (0.3755)
Buy
Beneish M-Score
(Annual)
Level (-3.1674)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (1.3957)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
MediPharm Labs Corp. is medicinal cannabis company, which engages in the pharmaceutical grade production of cannabis oil products. It focuses on the downstream secondary extraction methodology, distillation, and cannabinoid isolation and purification. It supplies raw materials, formulations, processing, and packaging for the creation of ready-to-sell derivative products. The company was founded by Patrick McCutcheon and Keith Strachan in 2015 and is headquartered in Barrie, Canada.
Stock Forecast FAQ
In the current month, LABS.TO has received 0 Buy ratings 1 Hold ratings, and 0 Sell ratings. The LABS.TO average analyst price target in the past 3 months is --.
-
Where Will MediPharm Labs Corp. Stock Be In 1 Year?
According to analysts, the consensus estimate is that MediPharm Labs Corp. share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About MediPharm Labs Corp.?
Analysts are divided on their view about MediPharm Labs Corp. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that MediPharm Labs Corp. is a Sell and believe this share price will drop from its current level to --.
-
What Is MediPharm Labs Corp.'s Price Target?
The price target for MediPharm Labs Corp. over the next 1-year time period is forecast to be -- according to 1 Wall Street analyst, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is LABS.TO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for MediPharm Labs Corp. is a Hold. 1 of 1 analysts rates the stock a Hold at this time.
-
How Can I Buy Shares Of LABS.TO?
You can purchase shares of MediPharm Labs Corp. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase MediPharm Labs Corp. shares.
-
What Is The MediPharm Labs Corp. Share Price Today?
MediPharm Labs Corp. was last trading at $0.08 per share. This represents the most recent stock quote for MediPharm Labs Corp.. Yesterday, MediPharm Labs Corp. closed at $0.08 per share.
-
How To Buy MediPharm Labs Corp. Stock Online?
In order to purchase MediPharm Labs Corp. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get LABS.TO Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
LABS.TO
Sector
P/E ratio
--
23.92x
PEG ratio
--
-0.01x
P/B ratio
0.83x
1.83x
Price / LTM sales
0.68x
1.61x
Growth Metrics
LABS.TO
Sector
Revenue growth
16.84%
4.6%
Earnings growth
25%
10.88%
Revenue (5-year growth)
-20.15%
6.46%
Earnings forecast
-$0.01
-$0.21
Profitability
LABS.TO
Sector
Profitability FY 2024
$11.3M
$3.5M
Return on invested capital
-18.99%
-31.84%
Return on assets
-15.58%
-27.96%
Return on equity
-19.19%
-37.63%
Earnings Date
Last Earnings Date
Nov
13
Next Earnings Date
Mar
30
Estimated Next Earnings Date
Feb
12
Balance Sheet
LABS.TO
Sector
Total cash
$10.6M
$26.3M
Short term investments
--
$25.7M
Total assets
$53.7M
$76.9M
Long term debt
$423K
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Sell
20
SMX alert for Dec 27
SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
